WINNIPEG, MANITOBA -- (MARKET WIRE) -- April 24, 2007 -- DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biotechnology company developing novel treatments for various stages of type 2 diabetes, is pleased to announce that it will be presenting at BioFinance 2007 in Toronto.
